Skip to main content

Advertisement

Log in

Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1

  • ORIGINAL ARTICLE
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

Many patients with gastric cancer respond to TS-1, but some fail to respond or have recurrence. Second-line therapy is needed.

Methods

We performed a pilot study in patients with advanced gastric cancer who did not respond to TS-1 or who had disease recurrence. The patients received oral doxifluridine (600 mg/day) on days 1 to 21 and an intravenous infusion of paclitaxel (70 mg/m2) on days 7, 14, and 21 of a 28-day cycle. The treatment was repeated until disease progression or prohibitive toxicity. Response rate, duration of response, median survival time (MST), effects on pleural effusion, ascites, and other signs, and toxicity were evaluated.

Results

The study group comprised 52 patients. The response rate was 28%. The duration of response was 103 days. The MST after the start of second-line treatment was 175 days (95% confidence interval, 135 to 224 days). Pleural effusion or ascites resolved or decreased in 73% of the patients. Hair loss occurred in 32 patients (62%), and leukopenia developed in 28 (54%, grade 3 in 1 patient and grade 2 or lower in the others). The MST after the start of treatment with TS-1 was about 16 months.

Conclusion

A combination of doxifluridine and weekly paclitaxel is expected to be an effective second-line treatment for gastric cancer not responding to TS-1, especially in patients with malignant ascites or pleural effusion. However, it remains unclear whether paclitaxel plus doxifluridine results in a better response and survival benefit than paclitaxel alone in this subgroup of patients. Further studies are therefore necessary.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Y Sakata A Ohtsu N Horikoshi et al. (1998) ArticleTitleLate phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients Eur J Cancer 34 1715–1720 Occurrence Handle9893658 Occurrence Handle10.1016/S0959-8049(98)00211-1 Occurrence Handle1:CAS:528:DyaK1cXntlShurw%3D

    Article  PubMed  CAS  Google Scholar 

  2. W Koizumi M Kurihara S Nakano et al. (2000) ArticleTitlePhase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group Oncology 58 191–197 Occurrence Handle10765119 Occurrence Handle10.1159/000012099 Occurrence Handle1:CAS:528:DC%2BD3cXjvVeitr4%3D

    Article  PubMed  CAS  Google Scholar 

  3. A Ohtsu N Boku F Tamura et al. (1998) ArticleTitleAn early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer Am J Clin Oncol 21 416–419 Occurrence Handle9708646 Occurrence Handle10.1097/00000421-199808000-00021 Occurrence Handle1:STN:280:DyaK1cznt1emsw%3D%3D

    Article  PubMed  CAS  Google Scholar 

  4. Y Yamada K Shirao A Ohtsu et al. (2001) ArticleTitlePhase II trial of paclitaxel by 3-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions Ann Oncol 12 1133–1137 Occurrence Handle11583196 Occurrence Handle10.1023/A:1011680507956 Occurrence Handle1:STN:280:DC%2BD3MrjsFehtQ%3D%3D

    Article  PubMed  CAS  Google Scholar 

  5. K Yamaguchi M Tada N Horikoshi et al. (2002) ArticleTitlePhase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer Gastric Cancer 5 90–95 Occurrence Handle12111584 Occurrence Handle10.1007/s101200200015 Occurrence Handle1:CAS:528:DC%2BD38XmslGlsbg%3D

    Article  PubMed  CAS  Google Scholar 

  6. AD Seidman CA Hudis J Albanel et al. (1998) ArticleTitleDose dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer J Clin Oncol 16 3353–3361 Occurrence Handle9779712 Occurrence Handle1:CAS:528:DyaK1cXmvFGrtbY%3D

    PubMed  CAS  Google Scholar 

  7. NR Abu-Rustum C Aghajanian RR Barakat et al. (1997) ArticleTitleSalvage weekly paclitaxel in recurrent ovarian cancer Semin Oncol 24 IssueID5 Suppl 15 S15-62–S15-67

    Google Scholar 

  8. AY Chang J Rubis R Asbury et al. (2001) ArticleTitleWeekly paclitaxel in advanced non-small cell lung cancer Semin Oncol 28 10–13 Occurrence Handle11605177 Occurrence Handle10.1053/sonc.2001.27607 Occurrence Handle1:CAS:528:DC%2BD3MXnvVCitrw%3D

    Article  PubMed  CAS  Google Scholar 

  9. N Sawada T Ishikawa Y Fukase et al. (1998) ArticleTitleInduction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts Clin Cancer Res 4 1013–1019 Occurrence Handle9563897 Occurrence Handle1:CAS:528:DyaK1cXisFeksr4%3D

    PubMed  CAS  Google Scholar 

  10. T Moriwaki I Hyodo T Nishina et al. (2005) ArticleTitleA phase I study of doxifluridine combined with weekly paclitaxel for metastatic gastric cancer Cancer Chemother Pharmacol 56 138–144 Occurrence Handle15827767 Occurrence Handle10.1007/s00280-004-0983-y Occurrence Handle1:CAS:528:DC%2BD2MXksl2hu7s%3D

    Article  PubMed  CAS  Google Scholar 

  11. I Takeyoshi F Makita Y Tanahashi et al. (2005) ArticleTitleA combination phase I study of weekly paclitaxel and doxifluridine in advanced gastric cancer patients Anticancer Res 25 1291–1296 Occurrence Handle15865080 Occurrence Handle1:CAS:528:DC%2BD2MXkt1Wnurg%3D

    PubMed  CAS  Google Scholar 

  12. N Saijyo K Kubota K Tobinai et al. (1999) ArticleTitleNational Cancer Institute – Common Toxicity Criteria (NCI-CTC version 2.0) – Japan Clinical Oncology Group Jpn J Cancer Chemother 26 IssueID8 1084–1144

    Google Scholar 

  13. P Therasse SG Arbuck EA Eisenhauer et al. (2000) ArticleTitleNew guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205–216 Occurrence Handle10655437 Occurrence Handle10.1093/jnci/92.3.205 Occurrence Handle1:STN:280:DC%2BD3c7it1Gitg%3D%3D

    Article  PubMed  CAS  Google Scholar 

  14. AM Murad FF Santiago A Petroianu et al. (1993) ArticleTitleModified therapy with 5-fluor-ouracil, doxorubicin, and methotrexate in advanced gastric cancer Cancer 72 37–41 Occurrence Handle8508427 Occurrence Handle10.1002/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P Occurrence Handle1:STN:280:ByyB1cvlvFM%3D

    Article  PubMed  CAS  Google Scholar 

  15. B Glimelius K Hoffman U Haglund et al. (1994) ArticleTitleInitial or delayed chemotherapy with best supportive care in advanced gastric cancer Ann Oncol 5 189–190 Occurrence Handle8186165 Occurrence Handle1:STN:280:ByuB2c3mvVY%3D

    PubMed  CAS  Google Scholar 

  16. S Pyrhonen T Kuitunen P Nyandoto et al. (1995) ArticleTitleRandomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer Br J Cancer 71 587–591 Occurrence Handle7533517 Occurrence Handle1:STN:280:ByqC1cnjvVA%3D

    PubMed  CAS  Google Scholar 

  17. W Koizumi S Tanabe K Saigenji et al. (2003) ArticleTitlePhase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer Br J Cancer 89 2207–2212 Occurrence Handle14676796 Occurrence Handle10.1038/sj.bjc.6601413 Occurrence Handle1:CAS:528:DC%2BD3sXpvVShtbc%3D

    Article  PubMed  CAS  Google Scholar 

  18. I Kokufu T Tanei H Taniguchi et al. (2002) ArticleTitleA case of effective weekly paclitaxel administration for metastatic gastric cancer Jpn J Cancer Chemother 29 2005–2008

    Google Scholar 

  19. Y Fujiwara S Tamura S Yoshioka et al. (2002) ArticleTitleThree case of advanced and recurrent gastric cancer treated with paclitaxel after TS-1 administration Jpn J Cancer Chemother 29 2555–2559

    Google Scholar 

  20. T Suzuki M Iwabuchi Y Matsuda et al. (2003) ArticleTitleTreatment outcomes with paclitaxel for advanced gastric cancer patients previously treated with TS-1 Jpn J Cancer Chemother 30 133–139

    Google Scholar 

  21. S Hironaka S Zenda N Boku et al. (2006) ArticleTitleWeekly paclitaxel as second-line chemotherapy for advanced or recurrent gastric cancer Gastric Cancer 9 14–18 Occurrence Handle16557431 Occurrence Handle10.1007/s10120-005-0351-6 Occurrence Handle1:CAS:528:DC%2BD28XivVeguro%3D

    Article  PubMed  CAS  Google Scholar 

  22. AF Cook MJ Holman MJ Kramer et al. (1979) ArticleTitleFluorinated pyrimidine nucleosides. 3. Synthesis and antitumor activity of a series of a 5′-deoxy-5-fluoropyrimidine nucleosides J Med Chem 22 1330–1335 Occurrence Handle533880 Occurrence Handle10.1021/jm00197a010 Occurrence Handle1:CAS:528:DyaE1MXlvVKmu7s%3D

    Article  PubMed  CAS  Google Scholar 

  23. H Ishitsuka M Miwa K Takemoto et al. (1980) ArticleTitleRole of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine Gann 71 23–34

    Google Scholar 

  24. M Miwa M Ura M Nishida et al. (1998) ArticleTitleDesign of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1274–1281 Occurrence Handle9849491 Occurrence Handle10.1016/S0959-8049(98)00058-6 Occurrence Handle1:CAS:528:DyaK1cXltlCgsrk%3D

    Article  PubMed  CAS  Google Scholar 

  25. T Ishikawa F Sekiguchi Y Fukase et al. (1998) ArticleTitlePositive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts Cancer Res 58 685–690 Occurrence Handle9485021 Occurrence Handle1:CAS:528:DyaK1cXht1antbc%3D

    PubMed  CAS  Google Scholar 

  26. I Takeyoshi K Iwanami T Yamada et al. (2005) ArticleTitleAdvanced gastric cancer with peritoneal dissemination successfully treated with paclitaxel and doxifluridine: a case report Hepatogastroenterology 52 322–325 Occurrence Handle15783060

    PubMed  Google Scholar 

  27. TM Loffler W Freund J Lipke TU Hausamen (1996) ArticleTitleSchedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial Semin Oncol 23 6 IssueIDSuppl 16 32–34

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Wataru Arai.

About this article

Cite this article

Arai, W., Hosoya, Y., Hyodo, M. et al. Doxifluridine combined with weekly paclitaxel for second-line treatment in patients with gastric cancer resistant to TS-1. Int J Clin Oncol 12, 146–149 (2007). https://doi.org/10.1007/s10147-006-0642-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-006-0642-x

Key words

Navigation